Ginkgo Bioworks Holdings, Inc. vs. Moderna, Inc. Common Stock
Moderna, Inc. Common Stock (MRNA) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| DNA | MRNA | |
|---|---|---|
| Market Cap | $863.98 million | $81.13 billion |
| Revenue (TTM) | $111.86 million | — |
| Net Income (TTM) | $-290,803,000 | — |
MRNA leads on 1 of 1 size & scale factors.
Valuation
| DNA | MRNA | |
|---|---|---|
| Price / Book | 2.06 | — |
| Price / Sales | 7.72 | — |
DNA and MRNA split the valuation factors evenly.
Profitability
| DNA | MRNA | |
|---|---|---|
| Net Margin | -259.96% | — |
| Return on Equity | -69.19% | — |
DNA and MRNA split the profitability factors evenly.
Risk & Sentiment
| DNA | MRNA | |
|---|---|---|
| Short Interest | 18.73% | 0.01% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: DNA overview, DNA financials, MRNA overview, MRNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.